|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||
| Current assets | ||||||||||
| Cash | ||||||||||
| Other receivable | ||||||||||
| Due from Sponsor | ||||||||||
| Prepaid expenses | ||||||||||
| Total current assets | ||||||||||
| Deferred offering costs | ||||||||||
| Investments held in Trust Account | ||||||||||
| TOTAL ASSETS | ||||||||||
| LIABILITIES AND SHAREHOLDERS' DEFICIT | ||||||||||
| Current liabilities | ||||||||||
| Accounts payable and accrued expenses | ||||||||||
| Accrued offering costs | ||||||||||
| Chinese taxes payable | ||||||||||
| Chinese income taxes payable | ||||||||||
| Chinese VAT and surcharges payable | ||||||||||
| Advances from Sponsor | ||||||||||
| Promissory note - Sponsor | ||||||||||
| Extension Note | ||||||||||
| Unsecured Promissory Note 2024 | ||||||||||
| Total promissory note - Sponsor | ||||||||||
| Extension Note - Sponsor | ||||||||||
| Extension Note | ||||||||||
| Total extension Note - Sponsor | ||||||||||
| TOTAL LIABILITIES | ||||||||||
| Ordinary shares subject to possible redemption, 652,170 shares at $11.57 and $11.36 per share redemption value as of March 31, 2025 and December 31, 2024, respectively | ||||||||||
| SHAREHOLDERS' DEFICIT | ||||||||||
| Ordinary shares, $0.0001 par value; 220,000,000 shares authorized; 2,548,000 issued and outstanding (excluding 652,170 shares subject to possible redemption) as of March 31, 2025 and December 31, 2024 | ||||||||||
| Additional paid-in capital | ||||||||||
| Accumulated deficit | ||||||||||
| TOTAL SHAREHOLDERS' DEFICIT | ||||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT |
Loading...
